AtomVie and Radiopharm Ventures Partner to Develop Targeted Radiopharmaceutical 177Lu-BetaBart

AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has entered into an agreeme...

October 16, 2024 | Wednesday | News
Jazz Pharmaceuticals Reports Positive Phase 3 Results for Zepzelca® Combined with Atezolizumab in Small Cell Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinected...

October 16, 2024 | Wednesday | News
Amgen Announces Positive Phase 3 Results for UPLIZNA® in Generalized Myasthenia Gravis, Paving the Way for New Treatment Options

Amgen (NASDAQ:AMGN) announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA&...

October 16, 2024 | Wednesday | News
Biofrontera Completes Treatment Phase in First U.S. Phase 3 PDT Study for sBCC, Data Analysis Underway

First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of m...

October 15, 2024 | Tuesday | News
Eli Lilly's Mirikizumab Shows Promising Histologic Response in Phase 3 Study for Crohn's Disease, Outperforming Ustekinumab

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with miri...

October 15, 2024 | Tuesday | News
Exelixis and MSD Announce Strategic Collaboration to Evaluate Zanzalintinib in Combination with KEYTRUDA® and WELIREG® for Advanced Cancers

Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the companies have entered i...

October 15, 2024 | Tuesday | News
BD and Hamilton Robotics Launch Automation-Ready Reagents to Transform Genomic Sequencing Workflows

  Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing&nb...

October 15, 2024 | Tuesday | News
Ardena Expands Global CDMO Footprint with Acquisition of Catalent’s Somerset Facility

  Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...

October 15, 2024 | Tuesday | News
Sherry Shao, Rotating CEO of GenScript, Celebrates MSCI's A Rating for Improved ESG Performance

"The A rating from MSCI is a significant recognition of our improvement in ESG performance," said Sherry Shao, Rotating CEO of GenScript. "We believe that ...

October 14, 2024 | Monday | News
Sandoz Launches First FDA-Approved Generic Paclitaxel for Metastatic Breast Cancer

First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic ...

October 14, 2024 | Monday | News
Aileron Therapeutics Showcases Promising LTI-03 Results for Idiopathic Pulmonary Fibrosis at ICLAF

Aileron Therapeutics,  a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...

October 14, 2024 | Monday | News
Pfizer Receives FDA Approval for HYMPAVZI™: A New Treatment for Hemophilia A and B

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis ...

October 14, 2024 | Monday | News
New MammoScreen® AI Enhances Breast Cancer Screening with Comprehensive Workflow Features

New MammoScreen® AI delivers a comprehensive suite of features including breast density and pre-reporting, creating the ultimate ...

October 11, 2024 | Friday | News
Andelyn Biosciences Partners with Hubble Therapeutics to Advance Gene Therapy for Rare Childhood Blindness

 Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been s...

October 11, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close